The Immunic Therapeutics AG, a clinical stage private biotech company in Martinsried near Munich, Germany, announced that it has completed its Series A round of financing now totaling 31.7 million euros of preferred stock financing. Omega Funds (Boston, MA, USA) and Fund+ (Leuven, Belgium) joined the existing international group of investors, led by LSP, with an additional EUR 10 million in equity financing. Immunic was founded in 2016 with the aim to bring promising drug development projects to clinical proof-of-concept. The company currently has two ongoing drug development programs – IMU-838 and IMU-366 – both in the field of Th17 and Th1 mediated chronic inflammatory and autoimmune diseases like ulcerative colitis, Crohn’s disease and psoriasis.